TSHA Graph | Taysha Gene Therapies, Inc.

TSHA Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $0.00; Research and development $38.64M; Operating expenses $47.35M; Income tax (m).
2026-03-31: Revenue $0.00; Research and development $33.81M; Operating expenses $43.49M; Income tax $0.00.
2025-12-31: Revenue $5.49M*; Research and development $24.95M*; Operating expenses $33.78M*; Income tax $0.00*.
2025-09-30: Revenue $0.00; Research and development $25.75M; Operating expenses $34.02M; Income tax (m).

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$0.00	$38.64M	$47.35M	(m)	-$46.64M
2026-03-31	$0.00	$33.81M	$43.49M	$0.00	-$42.41M
2025-12-31	$5.49M*	$24.95M*	$33.78M*	$0.00*	-$27.85M*
2025-09-30	$0.00	$25.75M	$34.02M	(m)	-$32.73M
2025-06-30	$1.99M	$20.14M	$28.74M	(m)	-$26.88M
2025-03-31	$2.30M	$15.56M	$23.72M	$0.00	-$21.53M
2024-09-30	$1.79M	$14.95M	$27.69M	(m)	-$25.52M
2024-06-30	$1.11M	$15.07M	$22.41M	(m)	-$20.93M
2024-03-31	$3.41M	$20.66M	$27.74M	$0.00	-$24.06M
2023-12-31	(m)	(m)	(m)	$0.00*	(m)
2023-09-30	$4.75M	$11.79M	$21.00M	(m)	-$117.09M
2023-06-30	$2.40M	$19.79M	$25.78M	(m)	-$24.60M
2023-03-31	$4.71M	$12.51M	$21.27M	$0.00	-$17.62M
2022-12-31	(m)	(m)	(m)	$0.00*	(m)
2022-09-30	(m)	$16.77M	$25.46M	(m)	-$26.53M
2022-06-30	(m)	$23.51M	$33.37M	(m)	-$34.09M
2022-03-31	(m)	$38.18M	$49.65M	$0.00	-$50.32M
2021-09-30	(m)	$39.53M	$50.68M	(m)	-$51.19M
2021-06-30	(m)	$30.64M	$40.77M	(m)	-$40.93M
2021-03-31	(m)	$23.85M	$32.09M	$0.00	-$32.02M
2020-09-30	(m)	$11.06M	$15.04M	(m)	-$15.04M
2020-06-30	(m)	$3.06M	$4.01M	(m)	-$21.22M
2020-03-31	(m)	$5.51M	$5.58M	(m)	-$5.43M
2019-12-31	(m)	$987.00K	$1.11M	(m)	-$1.11M

Revenue and expense 6 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$0.00	$72.44M	$90.83M	$0.00	-$89.05M
2025-06-30	$4.29M	$35.71M	$52.46M	$0.00	-$48.41M
2024-06-30	$4.52M	$35.73M	$50.15M	$0.00	-$44.99M
2023-06-30	$7.10M	$32.30M	$47.04M	$0.00	-$42.22M
2022-06-30	(m)	$61.69M	$83.02M	$0.00	-$84.41M
2021-06-30	(m)	$54.50M	$72.86M	$0.00	-$72.95M
2020-06-30	(m)	$8.58M	$9.59M	(m)	-$26.65M

Revenue and expense 9 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-09-30	$4.29M	$61.45M	$86.49M	$0.00	-$81.14M
2024-09-30	$6.31M	$50.68M	$77.84M	$0.00	-$70.51M
2023-09-30	$11.85M	$44.10M	$68.04M	$0.00	-$159.31M
2022-09-30	(m)	$78.46M	$108.48M	$0.00	-$110.94M
2021-09-30	(m)	$94.03M	$123.54M	$0.00	-$124.14M
2020-09-30	(m)	$19.63M	$24.64M	(m)	-$41.69M

Revenue and expense 12 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-12-31	$9.77M	$86.40M	$120.27M	$0.00	-$109.00M
2024-12-31	$8.33M	$66.00M	$99.79M	$0.00	-$89.30M
2023-12-31	$15.45M	$56.78M	$87.89M	$0.00	-$111.57M
2022-12-31	$2.50M	$91.17M	$164.95M	$0.00	-$166.01M
2021-12-31	(m)	$131.94M	$173.27M	(m)	-$174.52M
2020-12-31	(m)	$31.89M	$43.00M	$0.00	-$60.01M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Immunocore Holdings plc (IMCR)		$1.613B	-90.43
Inhibrx Biosciences, Inc. (INBX)	United States	$1.477B	-10.08
Maze Therapeutics, Inc. (MAZE)	United States	$1.457B	-12.40
Hemab Therapeutics Holdings, Inc. (COAG)	United States	$1.672B
NOVAVAX INC (NVAX)	United States	$1.748B	-6.26
Vir Biotechnology, Inc. (VIR)	United States	$1.814B	-6.85
Replimune Group, Inc. (REPL)	United States	$1.186B	-3.13
Vericel Corp (VCEL)	United States	$2.011B	93.97
Vor Biopharma Inc. (VOR)	United States	$1.091B	1.60
MeiraGTx Holdings plc (MGTX)	United States	$1.061B	16.10